Merz Pharmaceuticals Introduces Programs To Provide Patients With Financial Assistance For Xeomin
March 11, 2011 - Merz Pharmaceuticals announced the launch of two programs to provide financial assistance to patients for their treatment with Xeomin (incobotulinumtoxinA). Xeomin is a botulinum toxin type A that is approved by the US Food and Drug Administration (FDA) for the treatment of adults with cervical dystonia, to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naive and previously treated patients. Xeomin is also approved for the treatment of adults with blepharospasm who were previously treated with onabotulinumtoxinA (Botox).
The Xeomin Patient Co-payment Program offers eligible patients assistance for their actual out-of-pocket costs for therapeutic treatment with Xeomin. Eligible treatment-related costs may include the cost of Xeomin, associated guidance therapy, and related administration fees.
Merz also announced the launch of the Xeomin Patient Assistance Program, a program to provide Xeomin at no cost to eligible patients who are experiencing financial hardship and who do not have third party drug coverage.
Enrollment in the Xeomin Patient Co-payment Program or the Xeomin Patient Assistance Program is simple. Patients who want to learn more about the programs and secure an application form can do so by calling 888-4-XEOMIN (888-493-6646) or by speaking with their healthcare provider. Dedicated support representatives are available from 8 am until 8 pm (EST), Monday through Friday.
Xeomin (incobotulinumtoxinA) is a botulinum neurotoxin type A product. More than 84,000 patients have been treated with Xeomin worldwide since 2005. The US is the 20th country to approve Xeominfor the treatment of cervical dystonia and blepharospasm.
Xeominis the only botulinum toxin that does not require refrigeration prior to reconstitution. Xeomin is available in 50-unit and 100-unit vials, which Merz believes may allow for more precise billing and reduce wastage.
Merz Pharmaceuticals, LLC is a part of the Merz Group of companies and was established in 1995 to develop and commercialize products for the Merz Group. Areas of therapeutic focus include Neurology, Dermatology, and Podiatry. For more information, go to: http://www.merzusa.com/